Liver enzymes elevation and immune reconstitution among treatment-Naïve HIV-infected patients instituting antiretroviral therapy

American Journal of the Medical Sciences

Volumn 334, Issue 5, 2007, Pages 334-341

  Ofotokun, Ighovwerha ^a,d   Smithson, Sarah E ^a   Lu, Chengxing ^c   Easley, Kirk A ^c   Lennox, Jeffrey L ^a,b,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY CENTER FOR AIDS RESEARCH   (United States)

^c EMORY UNIVERSITY   (United States)

^d Grady Infectious Disease Program   (United States)

Author keywords

Antiretroviral drugs; Hepatotoxicity; HIV AIDS; Immune reconstitution; Liver enzymes elevation

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LIVER ENZYME; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICAL RECORD; RISK FACTOR; STATISTICAL MODEL; URBAN AREA; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; ENZYMOLOGY; HEPATITIS B; HEPATITIS C; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; BENZOXAZINES; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LAMIVUDINE; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STAVUDINE; ZIDOVUDINE;

EID: 38449100386     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31811ec780     Document Type: Article

References (37)

1. Bossi P. Colin D. Bricaire F. Hypersensitivity syndrome associated with efavirenz therapy Clin Infect Dis 30 2000 227 228
2. John M. Flexman J. French M.A. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 12 1998 2289 2293
3. Hammer S.M. Katzenstein D.A. Hughes M.D. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter: AIDS Clinical Trials Group Study 175 Study Team N Engl J Med 335 1996 1081 1090
4. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals: Delta Coordinating Committee Lancet 348 1996 283 291
5. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial Lancet 349 1997 1413 1421
6. Staszewski S. Keiser P. Montaner J. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial JAMA 285 2001 1155 1163
7. Brau N. Leaf H.L. Wieczorek R.L. Severe hepatitis in three AIDS patients treated with indinavir Lancet 349 1997 924 925
8. Matsuda J. Gohchi K. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir Lancet 350 1997 364
9. Arribas J.R. Ibanez C. Ruiz-Antoran B. Acute hepatitis in HIV-infected patients during ritonavir treatment AIDS 12 1998 1722 1724
10. Collier A.C. Coombs R.W. Schoenfeld D.A. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group N Engl J Med 334 1996 1011 1017
11. Markowitz M. Conant M. Hurley A. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1-protease, to treat HIV infection J Infect Dis 177 1998 1533 1540
12. Lenzo N.P. Garas B.A. French M.A. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report AIDS 11 1997 1294 1296
13. Regazzi M. Maserati R. Villani P. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects Antimicrob Agents Chemother 49 2005 643 649
14. Hsu A. Granneman G.R. Bertz R.J. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents Clin Pharmacokinet 35 1998 275 291
15. Veronese L. Rautaureau J. Sadler B.M. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function Antimicrob Agents Chemother 44 2000 821 826
16. Gisolf E.H. Dreezen C. Danner S.A. Risk factors for hepatotoxicity in HIV-1 infected patients receiving ritonavir and saquinavir with or without stavudine: Prometheus Study Group Clin Infect Dis 31 2000 1234 1239
17. den Brinker M. Wit F.W. Wertheim-van Dillen P.M. Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection AIDS 14 2000 2895 2902
18. Rodriguez-Rosado R. Garcia-Samaniego J. Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy AIDS 12 1998 1256
19. Sulkowski M.S. Thomas D.L. Chaisson R.E. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection JAMA 283 2000 74 80
20. Laird N.M. Ware J.H. Random effects models for longitudinal data Biometrics 38 1982 963 974
21. Centers for Diseas Control and Prevention: serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures: worldwide, ‘97-‘00 Morb Mortal Wkly Rep 49 2001 1153 1156
22. Martin-Carbonero L. Nunez M. Rios P. Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus coinfected patients is not related to immune reconstitution AIDS 16 2002 1423 1425
23. Stone S.F. Lee L. Keane N.M. Association of increased Hepatitis C virus (HCV)–specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus–HCV-coinfected patients JID 186 2002 1498 1502
24. Donnelly P.J. Walker R.M. Racz W.J. Inhibition of mitochondrial respiration in vivo is an early event in acetaminophen-induced hepatotoxicity Arch Toxicol 68 1994 110 118
25. Lee W.M. Drug-induced hepatotoxicity N Engl J Med 349 2003 474 485
26. Holt M. Ju C. Mechanisms of drug-induced liver injury AAPS J 8 2006 48 54
27. Zimmerman H.J. Drug-induced liver disease Clin Liver Dis 4 2000 73 96
28. Monforte A.A. Bugarini R. Pezzoti P. Low frequency of severe hepatotoxicity and associate with HCV coinfection in HIV-positive patients treated with HAART J Acquir Immune Defic Syndr 28 2001 114 123
29. Justice A.C. Wagner J.H. Fusco G.P. HIV Survival: liver function tests independently predict survival [abstract MoOrB1058]. 2002 XIV International AIDS Conference (Barcelona)
30. Wit F.W.N.M. Weverling G.J. Weel J. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy J Infect Dis 186 2002 23 31
31. Becker S. Liver toxicity in epidemiology cohorts Clinic Infect Dis 38 Suppl 2 2004 S49 55
32. Sulkowski M.S. Thomas D.L. Mehta S.H. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections Hepatology 35 2002 182 189
33. Saves M. Vandentorren S. Daucourt V. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine cohort, France, 1996–1998 AIDS 13 1999 F115 21
34. Martinez E. Blanco J.L. Arnaiz J.A. Hepatotoxicity in HIV-1–infected patients receiving nevirapine containing antiretroviral therapy AIDS 15 2001 1261 1268
35. Dieterich D.T. Robinson P.A. Love J. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors Clin Infect Dis 38 Suppl 2 2004 S80 9
36. Law W.P. Dore G.J. Duncombe C.J. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001 AIDS 17 2003 2191 2199
37. Sanne I, on behalf of the FTC-302 Study Investigators and the FTC-302 Independent Clinical Steering Committee Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor AIDS 14 Suppl 4 2000 S12